IndustryCompany release

Vertex lifts 2026 revenue guidance to $13.15–13.25bn after Crinetics deal closes

🇺🇸 Vertex Pharmaceuticals Inc / Ma (VRTX) · Mon 02 Nov 2026

Third-quarter revenue rose 12% to $3.44bn as the Crinetics acquisition completed, CASGEVY gained paediatric approvals and a US decision on povetacicept in IgAN draws near.

Vertex Pharmaceuticals reported third-quarter 2026 revenue of $3.44bn, a 12% increase on the same period a year earlier. The company also raised its full-year 2026 revenue guidance to a range of $13.15bn to $13.25bn.

The quarter included the 1 September completion of Vertex's acquisition of Crinetics. The deal adds PALSONIFY, a treatment for acromegaly, to the company's portfolio.

On the regulatory side, CASGEVY has been approved for children aged two and older. Separately, the US Food and Drug Administration is due to decide on povetacicept in IgA nephropathy (IgAN), with a PDUFA goal date of 30 November. A PDUFA date is the target by which the agency aims to complete its review of an application.

In market access, ALYFTREK gained reimbursement in seven more countries during the period, taking the total to 32.

What it means for your team

  • The 30 November PDUFA date for povetacicept in IgAN is the next regulatory milestone to watch for nephrology and market-access teams.
  • CASGEVY's approvals for children aged two and older widen the eligible population, which may matter for access planning and post-authorisation monitoring.
  • ALYFTREK's reimbursement in 32 countries shows continued progress in securing payer decisions across markets.
  • PALSONIFY's addition after the Crinetics close brings an acromegaly product under Vertex's regulatory and safety responsibilities.

Company's press release (SEC filing): Vertex Pharmaceuticals Inc / Ma ↗

Article written by VigiEye from the official source (Vertex Pharmaceuticals Inc / Ma). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →